Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deals Of The Week: Forma/Boehringer Ingelheim, Biogen/Isis, Alnylam/Arrowhead

Executive Summary

Industry business-development executives rang in the New Year with a half-dozen deals, including Forma’s second big partnership in six months and a joint licensing agreement between Alnylam and Arrowhead.


Related Content

Deals Of The Week Discusses Pharma’s Need For Disruptive Collaboration
Boehringer, Forma Strike Discovery Deal In Oncology
Biogen Strikes A Deal With Isis For Antisense Technology
Genentech Licenses A Cancer Metabolism Program From Forma, With Option To Buy
Alnylam CEO John Maraganore - An Interview With "The Pink Sheet" DAILY (Part 1 of 2)
Ipsen Confident in U.S. Neurology Push Despite Dysport Delay


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts